Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neurochem
Canadaneurochemistry.org ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Academic drug discovery project focused on developing positive allosteric modulators of EAAT3 for multiple sclerosis treatment, particularly targeting progressive MS and myelin repair. Project is in early stages with target validation ongoing.
- Modalities
- Small moleculeSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Neurochem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurochem.